# Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

> **NCT00028327** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 250 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lamivudine/Zidovudine
- **DRUG:** Nelfinavir mesylate
- **DRUG:** Efavirenz
- **DRUG:** Lamivudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00028327
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** 250 (—)
- **Last updated:** 2011-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028327, "Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00028327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*